Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis

March 10, 2021

Press Releases

Comments Off on Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis

GAITHERSBURG, MD, March 10, 2021 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to advancing therapies that address the global rise of multi-drug resistant infections, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for PhageBank™ phage therapy for the treatment of Diabetic Foot Osteomyelitis (DFO). “Advancing […]

Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ for the Treatment of Prosthetic Joint Infections

February 10, 2021

Press Releases

Comments Off on Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ for the Treatment of Prosthetic Joint Infections

– Phase 1/2 trial to be conducted at Mayo Clinic in Rochester, Minnesota, starting Q2 2021 – GAITHERSBURG, MD, February 10, 2021 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of bacterial and viral infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) […]

Adaptive Phage Therapeutics to Participate in the NobleCon17 Virtual Investor Conference

January 15, 2021

Press Releases

Comments Off on Adaptive Phage Therapeutics to Participate in the NobleCon17 Virtual Investor Conference

GAITHERSBURG, MD, January 15, 2021 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company will participate in the 17th Annual Small & Microcap Investor Conference (NobleCon17) being organized by Noble Financial Group, taking place virtually on January 19-20, 2021. Chief Executive Officer, Greg Merril, […]